GlassScriptPhysician profile
Elissa Hassman
NPI 1891199188
$2,162.48
in general payments reported to CMS, 2019-2025
29 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.36 · 2020: $50.38 · 2021: $158 · 2022: $416 · 2023: $259 · 2024: $502 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.02 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $592.60 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $428.36 | 2021-2025 | Cequa |
| Glaxosmithkline, LLC. | $272.95 | 2020-2025 | Shingrix |
| Amgen INC. | $120.33 | 2020-2025 | Tepezza |
| Alcon Vision LLC | $107.63 | 2025 | Tryptyr |
| Lensar, INC. | $91.49 | 2025 | Lensar Laser System |
| Novartis Pharmaceuticals Corporation | $68.94 | 2020-2023 | |
| Exact Sciences Corporation | $54.83 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $46.53 | 2022-2025 | Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.81 | 2021-2024 | Xifaxan |
| Tarsus Pharmaceuticals, INC. | $32.04 | 2024 | Xdemvy |
| Kowa Pharmaceuticals America, INC. | $28.21 | 2023 | Seglentis, Livalo |
| Echosens North America, INC. | $26.97 | 2024 | Fibroscan |
| Insulet Corporation | $24.86 | 2024 | Omnipod |
| Janssen Pharmaceuticals, INC | $19.17 | 2025 | Spravato |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.73 | 2024 | |
| Modernatx, INC. | $17.00 | 2025 | Mresvia |
| Seqirus USA INC | $16.98 | 2022 | |
| Janssen Biotech, INC. | $16.56 | 2025 | Tremfya |
| Coopervision INC. | $16.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.91 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.77 | 2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $13.27 | 2021 | |
| Pfizer INC. | $13.19 | 2024 | |
| Oyster Point Pharma, INC. | $12.75 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.31 | 2022 | |
| Carl Zeiss Meditec, INC. | $11.36 | 2019 | |
| Allergan, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elissa Hassman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.